Answers are grounded in this paper and cite their sources.
Introduction: PARP inhibitors (PARPi) have been developed clinically as a treatment for cancers with defects in the DNA repair processes controlled by the BRCA1 and BRCA2 tumour suppressor genes. Although the path from concept through to clinical approval for PARPi in breast cancer has not been straightforward, recent clinical trial data suggests that some of the enthusiasm for developing these drugs in this disease is starting to return.Areas covered: The authors review published pre-clinical and clinical data pertaining to the use of PARPi in breast cancer, including: mechanism of action of PARPi; predictive biomarkers associated with drug sensitivity; clinical trials of PARPi in breast cancer, and mechanisms of drug resistance and drug combination strategies.Expert commentary: The publication of phase III clinical trial data describing a progression free survival benefit in breast cancer patients with BRCA gene mutations treated with PARPi suggests that the comparative drought of clinical data in this setting is coming to an end. The task ahead is now to optimise PARPi therapy, identifying the ideal drug combinations to use with these agents as well as establishing the optimal stage and scheduling that should be used to achieve maximum benefit and manage the emergence of resistance.
No takes yet. Share an insight, caveat, or question.
Pettitt et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: